secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zymeworks Inc. (ZYME)
CIK:        0001937653
Form:       8-K
Filed at:   2024-06-10T23:59:59+00:00
Accession:  0001193125-24-158341
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

NMPA accepts zanidatamab BLA in China; Zymeworks earns $8M milestone from BeiGene
--------------------------------------------------------------------------------

- China's NMPA accepted BLA for zanidatamab in second-line HER2+ biliary tract cancer.
- Acceptance triggers $8 million milestone payment from partner BeiGene under Asia Pacific license.
- FDA previously granted priority review for same indication; PDUFA target date Nov 29, 2024.
- Zanidatamab is also being developed by Jazz Pharmaceuticals in the U.S.
- Milestone payment expected to be received following NMPA acceptance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1937653/000119312524158341/0001193125-24-158341-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1937653/000119312524158341/d761396d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-158341

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer